Lineage Cell Therapeutics, Inc. LCTX
We take great care to ensure that the data presented and summarized in this overview for Lineage Cell Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LCTX
View all-
Broadwood Capital Inc New York, NY41.7MShares$25.4 Million2.94% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$5.83 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.6MShares$5.25 Million0.0% of portfolio
-
Defender Capital, Llc.5MShares$3.05 Million1.58% of portfolio
-
Logos Global Management LP San Francisco, CA5MShares$3.05 Million0.6% of portfolio
-
Raffles Associates LP New York, NY4.51MShares$2.75 Million4.64% of portfolio
-
Geode Capital Management, LLC Boston, MA3.68MShares$2.24 Million0.0% of portfolio
-
State Street Corp Boston, MA2.61MShares$1.59 Million0.0% of portfolio
-
Mai Capital Management1.67MShares$1.02 Million0.02% of portfolio
-
Bank Of America Corp Charlotte, NC1.37MShares$837,1770.0% of portfolio
Latest Institutional Activity in LCTX
Top Purchases
Top Sells
About LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
Insider Transactions at LCTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 26
2024
|
George A. Samuel Iii General Counsel |
BUY
Open market or private purchase
|
Direct |
15,000
+40.34%
|
$0
$0.6 P/Share
|
|
Nov 26
2024
|
Jill Ann Howe Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
15,000
+37.04%
|
$0
$0.59 P/Share
|
|
Nov 22
2024
|
Michael H. Mulroy |
BUY
Open market or private purchase
|
Direct |
40,000
+11.81%
|
$0
$0.57 P/Share
|
|
Nov 21
2024
|
Brian M Culley President and CEO |
BUY
Open market or private purchase
|
Direct |
40,000
+17.03%
|
$0
$0.6 P/Share
|
|
Aug 16
2024
|
Jill Ann Howe Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
10,500
+50.0%
|
$0
$0.89 P/Share
|
|
May 24
2024
|
Brian M Culley President and CEO |
BUY
Open market or private purchase
|
Direct |
10,000
+6.07%
|
$10,000
$1.05 P/Share
|
|
Feb 11
2024
|
George A. Samuel Iii General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,490
-25.74%
|
$2,490
$1.08 P/Share
|
|
Feb 11
2024
|
George A. Samuel Iii General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,076
+38.58%
|
-
|
|
Feb 11
2024
|
Brian M Culley President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,806
-8.12%
|
$12,806
$1.08 P/Share
|
|
Feb 11
2024
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,249
+16.54%
|
-
|
|
Feb 08
2024
|
Don M Bailey |
BUY
Open market or private purchase
|
Indirect |
96,155
+37.71%
|
$96,155
$1.04 P/Share
|
|
Feb 06
2024
|
Broadwood Partners, L.P. Director |
BUY
Open market or private purchase
|
Indirect |
0
|
-
|
|
Feb 06
2024
|
Broadwood Partners, L.P. Director |
BUY
Open market or private purchase
|
Direct |
6,730,770
+13.91%
|
$6,730,770
$1.04 P/Share
|
|
Dec 29
2023
|
Anula Jayasuriya |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$10,000
$1.09 P/Share
|
|
Feb 11
2023
|
George A. Samuel Iii General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
2,478
-40.78%
|
$2,478
$1.35 P/Share
|
|
Feb 11
2023
|
George A. Samuel Iii General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
6,076
+50.0%
|
-
|
|
Feb 11
2023
|
Brian M Culley President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,744
-9.16%
|
$12,744
$1.35 P/Share
|
|
Feb 11
2023
|
Brian M Culley President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
31,249
+18.34%
|
-
|
|
Feb 11
2023
|
Gary S. Hogge SVP,Clinical & Medical Affairs |
SELL
Payment of exercise price or tax liability
|
Direct |
5,310
-40.78%
|
$5,310
$1.35 P/Share
|
|
Feb 11
2023
|
Gary S. Hogge SVP,Clinical & Medical Affairs |
BUY
Exercise of conversion of derivative security
|
Direct |
13,020
+50.0%
|
-
|
Last 12 Months Summary
| Open market or private purchase | 6.97M shares |
|---|---|
| Exercise of conversion of derivative security | 37.3K shares |
| Payment of exercise price or tax liability | 15.3K shares |
|---|